Payment overview · 2025
General Payments
$185.25
4 reported records · 4 companies
Healthcare provider profile · identity verified
Emmanuil Rakhmanchik, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1003845660
Verified facts
What the public records show
CMS Open Payments records show Emmanuil Rakhmanchik, MD received $185.25 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 67.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 67.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $29.44 | 15.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.84 | 9.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.97 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.25 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 108 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
279 | 39 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 662 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 595 | 117 |
| Metformin Hcl | Metformin Hcl | 477 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 450 | 95 |
| Omeprazole | Omeprazole | 386 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 332 | 65 |
| Losartan Potassium | Losartan Potassium | 303 | 52 |
| Eliquis | Apixaban | 279 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 44 |
| Furosemide | Furosemide | 244 | 43 |
| Allopurinol | Allopurinol | 235 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 233 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 50 |
| Hydralazine Hcl | Hydralazine Hcl | 194 | 31 |
| Simvastatin | Simvastatin | 190 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 183 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 78 |
| Dexlansoprazole Dr | Dexlansoprazole | 161 | 33 |
| Linzess | Linaclotide | 160 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 44 |
| Valsartan | Valsartan | 150 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 145 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 23 |
| Vascepa | Icosapent Ethyl | 121 | 19 |
| Synthroid | Levothyroxine Sodium | 118 | 20 |
| Enalapril Maleate | Enalapril Maleate | 117 | 25 |
| Lisinopril | Lisinopril | 111 | 28 |
| Nifedipine Er | Nifedipine | 109 | 11 |
| Creon | Lipase/Protease/Amylase | 108 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 20 |
| Potassium Chloride | Potassium Chloride | 98 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 17 |
| Glimepiride | Glimepiride | 91 | 18 |
| Azithromycin | Azithromycin | 88 | 77 |
| Zenpep | Lipase/Protease/Amylase | 86 | 17 |
| Finasteride | Finasteride | 85 | 16 |
| Carvedilol | Carvedilol | 84 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 84 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 20 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Spironolactone | Spironolactone | 71 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 67 | 17 |
| Meloxicam | Meloxicam | 65 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 13 |
| Memantine Hcl | Memantine Hcl | 61 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 11 |
| Clonidine Hcl | Clonidine Hcl | 60 | 15 |
| Glipizide Er | Glipizide | 59 | suppressed |
| Ibuprofen | Ibuprofen | 58 | 30 |
| Naproxen | Naproxen | 57 | 32 |
| Benazepril Hcl | Benazepril Hcl | 56 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 20 |
| Trazodone Hcl | Trazodone Hcl | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 50 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Gabapentin | Gabapentin | 48 | 15 |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 44 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Famotidine | Famotidine | 38 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 11 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | 15 |
| Dutasteride | Dutasteride | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | 11 |
| Clotrimazole | Clotrimazole | 31 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Colchicine | Colchicine | 29 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Dexilant | Dexlansoprazole | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 13 |
| Livalo | Pitavastatin Calcium | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Proctozone-Hc | Hydrocortisone | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Diovan | Valsartan | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Lactulose | Lactulose | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 21 | suppressed |
| Silenor | Doxepin Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Nexium | Esomeprazole Magnesium | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Bystolic | Nebivolol Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Tavaborole | Tavaborole | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Lamictal Xr | Lamotrigine | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.25 · 4 records | Amgen Inc. | CAMZYOS, CREON, EVENITY, GEMTESA, LINZESS | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error